Can a common diabetes drug fix MDS anemia?
NCT ID NCT07516847
First seen Apr 28, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This phase II trial tests whether dapagliflozin, a drug used for diabetes, can improve anemia in people with lower-risk myelodysplastic syndromes (MDS). Anemia is a major problem in MDS, causing fatigue and often requiring blood transfusions. The study will give 37 participants dapagliflozin daily for 24 weeks to see if it raises hemoglobin levels and reduces transfusion needs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin (Forxiga), a diabetes drug
What this could lead to
If it works, this could offer a new, well-tolerated option to treat anemia in MDS patients, reducing fatigue and the need for blood transfusions.
What could go wrong
This is a small, early-phase trial with only 37 participants and no placebo group. The drug may not improve hemoglobin levels, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.